PMC:7195088 / 14271-35170
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
643 | 410-416 | Gene | denotes | CYP3A4 | Gene:1576 |
644 | 8282-8288 | Gene | denotes | CYP3A4 | Gene:1576 |
653 | 515-523 | Species | denotes | patients | Tax:9606 |
654 | 555-563 | Species | denotes | patients | Tax:9606 |
655 | 1433-1441 | Species | denotes | patients | Tax:9606 |
656 | 1623-1631 | Species | denotes | patients | Tax:9606 |
657 | 1967-1975 | Species | denotes | patients | Tax:9606 |
658 | 2212-2220 | Species | denotes | patients | Tax:9606 |
659 | 2461-2469 | Species | denotes | patients | Tax:9606 |
660 | 3166-3174 | Species | denotes | patients | Tax:9606 |
661 | 3592-3600 | Species | denotes | patients | Tax:9606 |
662 | 3874-3882 | Species | denotes | patients | Tax:9606 |
663 | 4166-4174 | Species | denotes | patients | Tax:9606 |
664 | 4482-4490 | Species | denotes | patients | Tax:9606 |
665 | 4750-4758 | Species | denotes | patients | Tax:9606 |
666 | 5059-5067 | Species | denotes | patients | Tax:9606 |
667 | 5485-5493 | Species | denotes | patients | Tax:9606 |
668 | 5850-5858 | Species | denotes | patients | Tax:9606 |
669 | 6091-6099 | Species | denotes | patients | Tax:9606 |
670 | 6364-6372 | Species | denotes | patients | Tax:9606 |
671 | 6475-6485 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
672 | 6691-6699 | Species | denotes | patients | Tax:9606 |
673 | 6898-6906 | Species | denotes | patients | Tax:9606 |
674 | 7114-7122 | Species | denotes | patients | Tax:9606 |
675 | 7352-7360 | Species | denotes | patients | Tax:9606 |
676 | 7516-7524 | Species | denotes | patients | Tax:9606 |
677 | 7748-7756 | Species | denotes | patients | Tax:9606 |
678 | 8048-8056 | Species | denotes | patients | Tax:9606 |
679 | 8413-8421 | Species | denotes | patients | Tax:9606 |
680 | 8746-8754 | Species | denotes | patients | Tax:9606 |
681 | 8797-8805 | Species | denotes | patients | Tax:9606 |
682 | 8879-8887 | Species | denotes | patients | Tax:9606 |
728 | 328-347 | Chemical | denotes | Lopinavir/ritonavir | MESH:C558899 |
729 | 348-357 | Chemical | denotes | Lopinavir | MESH:D061466 |
730 | 395-404 | Chemical | denotes | Ritonavir | MESH:D019438 |
731 | 439-448 | Chemical | denotes | lopinavir | MESH:D061466 |
732 | 491-510 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
733 | 588-607 | Chemical | denotes | Lopinavir/ritonavir | MESH:C558899 |
734 | 1159-1178 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
735 | 1387-1406 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
736 | 1411-1429 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
737 | 1580-1585 | Chemical | denotes | ASC09 | |
738 | 1586-1595 | Chemical | denotes | ritonavir | MESH:D019438 |
739 | 1600-1619 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
740 | 1796-1802 | Chemical | denotes | oxygen | MESH:D010100 |
741 | 1825-1829 | Chemical | denotes | FiO2 | |
742 | 1904-1923 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
743 | 1928-1947 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
744 | 1953-1963 | Chemical | denotes | umifenovir | MESH:C086979 |
745 | 2126-2145 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
746 | 2150-2169 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
747 | 2175-2184 | Chemical | denotes | ribavirin | MESH:D012254 |
748 | 2407-2426 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
749 | 2431-2442 | Chemical | denotes | oseltamivir | MESH:D053139 |
750 | 2447-2457 | Chemical | denotes | umifenovir | MESH:C086979 |
751 | 2861-2880 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
752 | 3099-3109 | Chemical | denotes | carrimycin | |
753 | 3114-3133 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
754 | 3137-3147 | Chemical | denotes | umifenovir | MESH:C086979 |
755 | 3151-3162 | Chemical | denotes | chloroquine | MESH:D002738 |
756 | 3449-3468 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
757 | 3473-3492 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
758 | 3744-3763 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
759 | 3797-3816 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
760 | 3851-3860 | Chemical | denotes | xiyanping | |
761 | 4026-4045 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
762 | 4079-4098 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
763 | 4326-4345 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
764 | 4351-4369 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
765 | 4374-4393 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
766 | 4399-4417 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
767 | 4423-4433 | Chemical | denotes | levamisole | MESH:D007978 |
768 | 4444-4454 | Chemical | denotes | budesonide | MESH:D019819 |
769 | 4460-4470 | Chemical | denotes | formoterol | MESH:D000068759 |
770 | 4678-4697 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
771 | 4702-4720 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
772 | 4725-4733 | Chemical | denotes | losartan | MESH:D019808 |
773 | 4929-4948 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
774 | 4953-4971 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
775 | 4976-4995 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
776 | 5024-5034 | Chemical | denotes | remdesivir | MESH:C000606551 |
777 | 5225-5244 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
778 | 5248-5258 | Chemical | denotes | umifenovir | MESH:C086979 |
779 | 5262-5273 | Chemical | denotes | chloroquine | MESH:D002738 |
780 | 5277-5295 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
781 | 5299-5310 | Chemical | denotes | oseltamivir | MESH:D053139 |
782 | 5328-5340 | Chemical | denotes | azithromycin | MESH:D017963 |
783 | 5365-5384 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
784 | 5388-5398 | Chemical | denotes | umifenovir | MESH:C086979 |
785 | 5402-5413 | Chemical | denotes | chloroquine | MESH:D002738 |
786 | 5417-5435 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
787 | 5439-5450 | Chemical | denotes | oseltamivir | MESH:D053139 |
788 | 5468-5480 | Chemical | denotes | azithromycin | MESH:D017963 |
789 | 5771-5781 | Chemical | denotes | colchicine | MESH:D003078 |
790 | 5799-5818 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
791 | 6068-6087 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
792 | 6126-6145 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
793 | 6225-6244 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
794 | 6525-6535 | Chemical | denotes | Remdesivir | MESH:C000606551 |
795 | 6536-6545 | Chemical | denotes | Adenosine | MESH:D000241 |
796 | 6665-6675 | Chemical | denotes | remdesivir | MESH:C000606551 |
797 | 6872-6882 | Chemical | denotes | remdesivir | MESH:C000606551 |
798 | 7073-7083 | Chemical | denotes | remdesivir | MESH:C000606551 |
799 | 7242-7248 | Chemical | denotes | oxygen | MESH:D010100 |
800 | 7311-7321 | Chemical | denotes | remdesivir | MESH:C000606551 |
801 | 7490-7500 | Chemical | denotes | remdesivir | MESH:C000606551 |
802 | 7672-7682 | Chemical | denotes | remdesivir | MESH:C000606551 |
803 | 7687-7705 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
804 | 7710-7720 | Chemical | denotes | remdesivir | MESH:C000606551 |
805 | 7726-7744 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
806 | 7918-7937 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
807 | 7942-7960 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
808 | 7965-7984 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
809 | 8013-8023 | Chemical | denotes | remdesivir | MESH:C000606551 |
810 | 8198-8207 | Chemical | denotes | Darunavir | MESH:D000069454 |
811 | 8208-8228 | Chemical | denotes | cobicistat Darunavir | |
812 | 8311-8320 | Chemical | denotes | darunavir | MESH:D000069454 |
813 | 8604-8615 | Chemical | denotes | Favipiravir | MESH:C462182 |
814 | 8768-8779 | Chemical | denotes | favipiravir | MESH:C462182 |
815 | 8816-8826 | Chemical | denotes | umifenovir | MESH:C086979 |
816 | 8898-8909 | Chemical | denotes | favipiravir | MESH:C462182 |
905 | 251-259 | Disease | denotes | COVID-19 | MESH:C000657245 |
906 | 569-577 | Disease | denotes | COVID-19 | MESH:C000657245 |
907 | 1003-1012 | Disease | denotes | mortality | MESH:D003643 |
908 | 1452-1460 | Disease | denotes | COVID-19 | MESH:C000657245 |
909 | 1647-1655 | Disease | denotes | COVID-19 | MESH:C000657245 |
910 | 1981-1989 | Disease | denotes | COVID-19 | MESH:C000657245 |
911 | 2226-2234 | Disease | denotes | COVID-19 | MESH:C000657245 |
912 | 2485-2503 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
913 | 2611-2616 | Disease | denotes | fever | MESH:D005334 |
914 | 2618-2623 | Disease | denotes | cough | MESH:D003371 |
915 | 2691-2696 | Disease | denotes | fever | MESH:D005334 |
916 | 2698-2703 | Disease | denotes | cough | MESH:D003371 |
917 | 2926-2934 | Disease | denotes | COVID-19 | MESH:C000657245 |
918 | 3050-3058 | Disease | denotes | COVID-19 | MESH:C000657245 |
919 | 3180-3198 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
920 | 3273-3278 | Disease | denotes | fever | MESH:D005334 |
921 | 3319-3341 | Disease | denotes | pulmonary inflammation | MESH:D011014 |
922 | 3606-3614 | Disease | denotes | COVID-19 | MESH:C000657245 |
923 | 3888-3896 | Disease | denotes | COVID-19 | MESH:C000657245 |
924 | 4180-4188 | Disease | denotes | COVID-19 | MESH:C000657245 |
925 | 4506-4524 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
926 | 4764-4772 | Disease | denotes | COVID-19 | MESH:C000657245 |
927 | 4860-4868 | Disease | denotes | COVID-19 | MESH:C000657245 |
928 | 5073-5081 | Disease | denotes | COVID-19 | MESH:C000657245 |
929 | 5499-5507 | Disease | denotes | COVID-19 | MESH:C000657245 |
930 | 5626-5631 | Disease | denotes | fever | MESH:D005334 |
931 | 5701-5718 | Disease | denotes | lung inflammation | MESH:D011014 |
932 | 5883-5891 | Disease | denotes | COVID-19 | MESH:C000657245 |
933 | 5971-5980 | Disease | denotes | mortality | MESH:D003643 |
934 | 6110-6118 | Disease | denotes | COVID-19 | MESH:C000657245 |
935 | 6317-6348 | Disease | denotes | ritonavir plus favipiravir plus | MESH:D007625 |
936 | 6397-6405 | Disease | denotes | COVID-19 | MESH:C000657245 |
937 | 6712-6720 | Disease | denotes | COVID-19 | MESH:C000657245 |
938 | 6929-6937 | Disease | denotes | COVID-19 | MESH:C000657245 |
939 | 7135-7143 | Disease | denotes | COVID-19 | MESH:C000657245 |
940 | 7218-7223 | Disease | denotes | fever | MESH:D005334 |
941 | 7375-7383 | Disease | denotes | COVID-19 | MESH:C000657245 |
942 | 7530-7538 | Disease | denotes | COVID-19 | MESH:C000657245 |
943 | 7762-7770 | Disease | denotes | COVID-19 | MESH:C000657245 |
944 | 7871-7880 | Disease | denotes | mortality | MESH:D003643 |
945 | 8062-8070 | Disease | denotes | COVID-19 | MESH:C000657245 |
946 | 8427-8445 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
947 | 8737-8745 | Disease | denotes | COVID-19 | MESH:C000657245 |
948 | 8788-8796 | Disease | denotes | COVID-19 | MESH:C000657245 |
1015 | 158-166 | Disease | denotes | COVID-19 | MESH:C000657245 |
1022 | 20273-20281 | Species | denotes | patients | Tax:9606 |
1023 | 20337-20348 | Chemical | denotes | ruxolitinib | MESH:C540383 |
1024 | 20350-20361 | Chemical | denotes | baricitinib | MESH:C000596027 |
1025 | 20366-20377 | Chemical | denotes | tofacitinib | MESH:C479163 |
1026 | 20133-20141 | Disease | denotes | COVID-19 | MESH:C000657245 |
1027 | 20287-20295 | Disease | denotes | COVID-19 | MESH:C000657245 |
1035 | 20571-20575 | Gene | denotes | IL-1 | Gene:3552 |
1036 | 20577-20590 | Gene | denotes | interleukin 1 | Gene:3552 |
1037 | 20807-20817 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1038 | 20819-20866 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
1039 | 20380-20384 | Disease | denotes | ARDS | MESH:D012128 |
1040 | 20387-20422 | Disease | denotes | acute respiratory distress syndrome | MESH:D012128 |
1041 | 20459-20483 | Disease | denotes | coronavirus disease 2019 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T7 | 364-367 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
T8 | 2666-2670 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T9 | 2746-2750 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T10 | 2808-2812 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T11 | 3406-3412 | Body_part | denotes | throat | http://purl.org/sig/ont/fma/fma228738 |
T12 | 5701-5705 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T13 | 6568-6571 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T14 | 6582-6585 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T15 | 6612-6615 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T16 | 8235-8238 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
T17 | 8535-8541 | Body_part | denotes | throat | http://purl.org/sig/ont/fma/fma228738 |
T18 | 8549-8555 | Body_part | denotes | sputum | http://purl.org/sig/ont/fma/fma312401 |
T19 | 8559-8582 | Body_part | denotes | lower respiratory tract | http://purl.org/sig/ont/fma/fma45662 |
T20 | 8631-8634 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T21 | 8645-8648 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T22 | 10256-10262 | Body_part | denotes | sputum | http://purl.org/sig/ont/fma/fma312401 |
T23 | 11714-11723 | Body_part | denotes | endosomal | http://purl.org/sig/ont/fma/fma67180 |
T24 | 11756-11760 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T25 | 11808-11812 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T26 | 14798-14804 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T27 | 15064-15067 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T28 | 15126-15129 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T29 | 15533-15541 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
T30 | 15694-15702 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
T31 | 15890-15894 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T32 | 16669-16671 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
T33 | 16685-16693 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T34 | 16885-16893 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T35 | 16948-16950 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
T36 | 16964-16966 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
T37 | 17064-17072 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
T38 | 18427-18440 | Body_part | denotes | interleukin 6 | http://purl.org/sig/ont/fma/fma264829 |
T39 | 18427-18438 | Body_part | denotes | interleukin | http://purl.org/sig/ont/fma/fma86578 |
T40 | 18463-18471 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T41 | 18734-18738 | Body_part | denotes | IL-1 | http://purl.org/sig/ont/fma/fma86583 |
T42 | 18734-18736 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
T43 | 19323-19329 | Body_part | denotes | throat | http://purl.org/sig/ont/fma/fma228738 |
T44 | 19373-19377 | Body_part | denotes | IL-1 | http://purl.org/sig/ont/fma/fma86583 |
T45 | 19373-19375 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
T46 | 19388-19392 | Body_part | denotes | IL-1 | http://purl.org/sig/ont/fma/fma86583 |
T47 | 19388-19390 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
T48 | 19474-19482 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
T49 | 19587-19595 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T50 | 19796-19800 | Body_part | denotes | IL-1 | http://purl.org/sig/ont/fma/fma86583 |
T51 | 19796-19798 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
T52 | 20555-20569 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
T53 | 20571-20575 | Body_part | denotes | IL-1 | http://purl.org/sig/ont/fma/fma86583 |
T54 | 20571-20573 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
T55 | 20577-20590 | Body_part | denotes | interleukin 1 | http://purl.org/sig/ont/fma/fma86583 |
T56 | 20577-20588 | Body_part | denotes | interleukin | http://purl.org/sig/ont/fma/fma86578 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T5 | 2666-2670 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T6 | 2746-2750 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T7 | 2808-2812 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T8 | 3406-3412 | Body_part | denotes | throat | http://purl.obolibrary.org/obo/UBERON_0000341 |
T9 | 4886-4891 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T10 | 5192-5197 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T11 | 5701-5705 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T12 | 6824-6829 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T13 | 7639-7644 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T14 | 8181-8186 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T15 | 8535-8541 | Body_part | denotes | throat | http://purl.obolibrary.org/obo/UBERON_0000341 |
T16 | 8549-8555 | Body_part | denotes | sputum | http://purl.obolibrary.org/obo/UBERON_0007311 |
T17 | 8559-8582 | Body_part | denotes | lower respiratory tract | http://purl.obolibrary.org/obo/UBERON_0001558 |
T18 | 8565-8582 | Body_part | denotes | respiratory tract | http://purl.obolibrary.org/obo/UBERON_0000065 |
T19 | 10256-10262 | Body_part | denotes | sputum | http://purl.obolibrary.org/obo/UBERON_0007311 |
T20 | 14255-14260 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T21 | 14742-14747 | Body_part | denotes | Scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T22 | 15437-15442 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T23 | 15890-15894 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T24 | 17299-17304 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T25 | 17360-17365 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T26 | 17755-17760 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T27 | 19323-19329 | Body_part | denotes | throat | http://purl.obolibrary.org/obo/UBERON_0000341 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T15 | 1656-1666 | Phenotype | denotes | pneumoniae | http://purl.obolibrary.org/obo/HP_0002090 |
T16 | 2494-2503 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T17 | 2611-2616 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
T18 | 2618-2623 | Phenotype | denotes | cough | http://purl.obolibrary.org/obo/HP_0012735 |
T19 | 2691-2696 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
T20 | 2698-2703 | Phenotype | denotes | cough | http://purl.obolibrary.org/obo/HP_0012735 |
T21 | 3189-3198 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T22 | 3273-3278 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
T23 | 4515-4524 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T24 | 5626-5631 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
T25 | 7218-7223 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
T26 | 8436-8445 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T27 | 11492-11501 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T28 | 15533-15547 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
T29 | 15590-15599 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T30 | 18228-18234 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T31 | 19106-19115 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T32 | 19190-19195 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
T33 | 19474-19499 | Phenotype | denotes | cytokine-release syndrome | http://purl.obolibrary.org/obo/HP_0033041 |
T34 | 20393-20413 | Phenotype | denotes | respiratory distress | http://purl.obolibrary.org/obo/HP_0002098 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T73 | 158-166 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T74 | 251-259 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T75 | 569-577 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T76 | 1452-1460 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T77 | 1647-1655 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T78 | 1656-1666 | Disease | denotes | pneumoniae | http://purl.obolibrary.org/obo/MONDO_0005249 |
T79 | 1981-1989 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T80 | 2226-2234 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T81 | 2485-2493 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T82 | 2494-2503 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T83 | 2926-2934 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T84 | 3050-3058 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T85 | 3180-3188 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T86 | 3189-3198 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T87 | 3329-3341 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
T88 | 3606-3614 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T89 | 3888-3896 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T90 | 4180-4188 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T91 | 4506-4514 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T92 | 4515-4524 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T93 | 4764-4772 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T94 | 4860-4868 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T95 | 5073-5081 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T96 | 5499-5507 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T97 | 5706-5718 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
T98 | 5883-5891 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T99 | 6110-6118 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T100 | 6397-6405 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T101 | 6475-6483 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T102 | 6712-6720 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T103 | 6929-6937 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T104 | 7135-7143 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T105 | 7375-7383 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T106 | 7530-7538 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T107 | 7762-7770 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T108 | 8062-8070 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T109 | 8427-8435 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T110 | 8436-8445 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T111 | 8621-8630 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T112 | 8737-8745 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T113 | 8788-8796 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T114 | 9077-9085 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T115 | 9291-9299 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T116 | 9578-9586 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T117 | 9656-9664 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T118 | 9805-9813 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T119 | 10065-10073 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T120 | 10357-10365 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T121 | 10638-10646 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T122 | 10925-10933 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T123 | 11003-11011 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T124 | 11069-11078 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T125 | 11172-11180 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T126 | 11223-11231 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T127 | 11483-11491 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T128 | 11492-11501 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T129 | 12274-12282 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T130 | 12393-12401 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T131 | 12503-12511 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T132 | 12660-12668 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T133 | 12938-12946 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T134 | 13016-13024 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T135 | 13136-13144 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T136 | 13292-13300 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T137 | 13341-13349 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T138 | 13531-13539 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T139 | 13655-13663 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T140 | 13789-13797 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T141 | 13913-13921 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T142 | 13924-13933 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T143 | 14020-14028 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T144 | 14172-14180 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T145 | 14378-14386 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T146 | 14620-14628 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T147 | 14716-14724 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T148 | 14918-14926 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T149 | 15068-15076 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T150 | 15318-15326 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T151 | 15508-15516 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T152 | 15542-15556 | Disease | denotes | storm syndrome | http://purl.obolibrary.org/obo/MONDO_0008496 |
T153 | 15590-15599 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T154 | 15601-15605 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
T155 | 15807-15815 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T156 | 15895-15901 | Disease | denotes | injury | http://purl.obolibrary.org/obo/MONDO_0021178 |
T157 | 15999-16007 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T158 | 16299-16307 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T159 | 16502-16510 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T160 | 16735-16743 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T161 | 17114-17122 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T162 | 17205-17213 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T163 | 17462-17470 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T164 | 17638-17646 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T165 | 17899-17907 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T166 | 18217-18234 | Disease | denotes | metastatic cancer | http://purl.obolibrary.org/obo/MONDO_0024880 |
T167 | 18228-18234 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T168 | 18239-18247 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T169 | 18526-18534 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T170 | 18872-18880 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T171 | 19097-19105 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T172 | 19106-19115 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T173 | 19246-19258 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
T174 | 19635-19643 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T175 | 19934-19942 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T176 | 20133-20141 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T177 | 20287-20295 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T178 | 20380-20384 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
T179 | 20387-20422 | Disease | denotes | acute respiratory distress syndrome | http://purl.obolibrary.org/obo/MONDO_0006502 |
T180 | 20393-20422 | Disease | denotes | respiratory distress syndrome | http://purl.obolibrary.org/obo/MONDO_0009971 |
T181 | 20449-20457 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T182 | 20459-20483 | Disease | denotes | coronavirus disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T183 | 20807-20815 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T184 | 20819-20866 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T185 | 20819-20852 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T49 | 101-106 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T50 | 408-409 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T51 | 471-476 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T52 | 1064-1068 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arms |
T53 | 1186-1187 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T54 | 1359-1361 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T55 | 1367-1369 | http://purl.obolibrary.org/obo/CLO_0050507 | denotes | 22 |
T56 | 1467-1472 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T57 | 1522-1527 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T58 | 1540-1544 | http://purl.obolibrary.org/obo/CLO_0001000 | denotes | 3, 5 |
T59 | 1560-1562 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
T60 | 1673-1678 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T61 | 1780-1786 | http://purl.obolibrary.org/obo/CLO_0001230 | denotes | 2 ≤ 93 |
T62 | 1780-1786 | http://purl.obolibrary.org/obo/CLO_0037237 | denotes | 2 ≤ 93 |
T63 | 1780-1786 | http://purl.obolibrary.org/obo/CLO_0050903 | denotes | 2 ≤ 93 |
T64 | 1780-1786 | http://purl.obolibrary.org/obo/CLO_0054249 | denotes | 2 ≤ 93 |
T65 | 1780-1786 | http://purl.obolibrary.org/obo/CLO_0054250 | denotes | 2 ≤ 93 |
T66 | 1780-1786 | http://purl.obolibrary.org/obo/CLO_0054251 | denotes | 2 ≤ 93 |
T67 | 1780-1786 | http://purl.obolibrary.org/obo/CLO_0054252 | denotes | 2 ≤ 93 |
T68 | 1996-2001 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T69 | 2059-2064 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T70 | 2241-2246 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T71 | 2510-2515 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T72 | 2567-2568 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T73 | 2666-2670 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T74 | 2666-2670 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T75 | 2746-2750 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T76 | 2746-2750 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T77 | 2759-2765 | http://purl.obolibrary.org/obo/CLO_0001230 | denotes | 2 > 93 |
T78 | 2759-2765 | http://purl.obolibrary.org/obo/CLO_0037237 | denotes | 2 > 93 |
T79 | 2759-2765 | http://purl.obolibrary.org/obo/CLO_0050903 | denotes | 2 > 93 |
T80 | 2759-2765 | http://purl.obolibrary.org/obo/CLO_0054249 | denotes | 2 > 93 |
T81 | 2759-2765 | http://purl.obolibrary.org/obo/CLO_0054250 | denotes | 2 > 93 |
T82 | 2759-2765 | http://purl.obolibrary.org/obo/CLO_0054251 | denotes | 2 > 93 |
T83 | 2759-2765 | http://purl.obolibrary.org/obo/CLO_0054252 | denotes | 2 > 93 |
T84 | 2797-2798 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T85 | 2808-2812 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T86 | 2808-2812 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T87 | 3020-3021 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T88 | 3205-3210 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T89 | 3270-3271 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T90 | 3316-3317 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T91 | 3543-3544 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T92 | 3621-3626 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T93 | 3903-3908 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T94 | 4195-4200 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T95 | 4599-4600 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T96 | 4630-4631 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T97 | 5174-5177 | http://purl.obolibrary.org/obo/CLO_0001608 | denotes | a 7 |
T98 | 5581-5582 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T99 | 5623-5624 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T100 | 5701-5705 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T101 | 5701-5705 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T102 | 5898-5903 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T103 | 6412-6417 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T104 | 7150-7155 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T105 | 7390-7395 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T106 | 7621-7624 | http://purl.obolibrary.org/obo/CLO_0050154 | denotes | a 8 |
T107 | 7777-7782 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T108 | 8163-8166 | http://purl.obolibrary.org/obo/CLO_0001608 | denotes | a 7 |
T109 | 8280-8281 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T110 | 8452-8457 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T111 | 8559-8582 | http://purl.obolibrary.org/obo/UBERON_0001558 | denotes | lower respiratory tract |
T112 | 8675-8676 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T113 | 8701-8702 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T114 | 8964-8968 | http://purl.obolibrary.org/obo/CLO_0008416 | denotes | peer |
T115 | 8964-8968 | http://purl.obolibrary.org/obo/CLO_0050081 | denotes | peer |
T116 | 9092-9097 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T117 | 9593-9598 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T118 | 9820-9825 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T119 | 9922-9923 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T120 | 10139-10140 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T121 | 10231-10232 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T122 | 10372-10377 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T123 | 10454-10458 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
T124 | 10940-10945 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T125 | 11079-11087 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T126 | 11110-11111 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T127 | 11136-11137 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T128 | 11399-11403 | http://purl.obolibrary.org/obo/CLO_0008416 | denotes | peer |
T129 | 11399-11403 | http://purl.obolibrary.org/obo/CLO_0050081 | denotes | peer |
T130 | 11508-11513 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T131 | 11571-11576 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T132 | 11745-11750 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T133 | 11756-11760 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T134 | 11808-11812 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T135 | 11841-11849 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T136 | 11993-11994 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T137 | 12067-12072 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T138 | 12147-12148 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T139 | 12209-12210 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T140 | 12675-12680 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T141 | 12740-12741 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T142 | 12787-12788 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T143 | 12953-12958 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T144 | 13049-13054 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T145 | 13271-13272 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T146 | 13312-13314 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
T147 | 13324-13325 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T148 | 13361-13363 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
T149 | 13406-13408 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
T150 | 13451-13453 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
T151 | 13883-13884 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T152 | 14144-14145 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T153 | 14215-14216 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T154 | 14237-14240 | http://purl.obolibrary.org/obo/CLO_0001577 | denotes | a 3 |
T155 | 14393-14398 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T156 | 14798-14804 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T157 | 14933-14938 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T158 | 14998-14999 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T159 | 15011-15016 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T160 | 15051-15052 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T161 | 15419-15422 | http://purl.obolibrary.org/obo/CLO_0001608 | denotes | a 7 |
T162 | 15473-15474 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T163 | 15531-15532 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T164 | 15822-15827 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T165 | 15890-15894 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T166 | 15890-15894 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T167 | 16014-16019 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T168 | 16517-16522 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T169 | 16574-16575 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T170 | 16608-16609 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T171 | 16750-16755 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T172 | 16859-16868 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | Humanized |
T173 | 16921-16929 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T174 | 17086-17089 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T175 | 17220-17225 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T176 | 17341-17345 | http://purl.obolibrary.org/obo/CLO_0001550 | denotes | a 10 |
T177 | 17477-17482 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T178 | 17737-17740 | http://purl.obolibrary.org/obo/CLO_0001608 | denotes | a 7 |
T179 | 17914-17919 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T180 | 17979-17980 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T181 | 18026-18027 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T182 | 18254-18259 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T183 | 18427-18440 | http://purl.obolibrary.org/obo/PR_000001393 | denotes | interleukin 6 |
T184 | 18541-18546 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T185 | 18887-18892 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T186 | 19122-19127 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T187 | 19187-19188 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T188 | 19233-19234 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T189 | 19650-19655 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T190 | 19949-19954 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T191 | 20066-20071 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T192 | 20577-20590 | http://purl.obolibrary.org/obo/PR_000001091 | denotes | interleukin 1 |
T193 | 20686-20694 | http://purl.obolibrary.org/obo/UBERON_0001637 | denotes | arterial |
T194 | 20686-20694 | http://www.ebi.ac.uk/efo/EFO_0000814 | denotes | arterial |
T195 | 20886-20898 | http://purl.obolibrary.org/obo/OBI_0000245 | denotes | Organization |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T66 | 56-79 | Chemical | denotes | anti-inflammatory drugs | http://purl.obolibrary.org/obo/CHEBI_35472 |
T67 | 74-79 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T68 | 101-106 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T69 | 328-337 | Chemical | denotes | Lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T70 | 338-347 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T71 | 348-357 | Chemical | denotes | Lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T72 | 375-393 | Chemical | denotes | protease inhibitor | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
T74 | 384-393 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T75 | 410-426 | Chemical | denotes | CYP3A4 inhibitor | http://purl.obolibrary.org/obo/CHEBI_86501 |
T76 | 417-426 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T77 | 439-448 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T78 | 471-476 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T79 | 491-510 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T80 | 491-500 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T81 | 501-510 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T82 | 588-597 | Chemical | denotes | Lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T83 | 598-607 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T84 | 1159-1178 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T85 | 1159-1168 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T86 | 1169-1178 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T87 | 1387-1406 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T88 | 1387-1396 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T89 | 1397-1406 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T90 | 1411-1429 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T91 | 1467-1472 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T92 | 1586-1595 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T93 | 1600-1619 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T94 | 1600-1609 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T95 | 1610-1619 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T96 | 1673-1678 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T97 | 1796-1802 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T98 | 1839-1841 | Chemical | denotes | Hg | http://purl.obolibrary.org/obo/CHEBI_16170|http://purl.obolibrary.org/obo/CHEBI_25195 |
T100 | 1904-1923 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T101 | 1904-1913 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T102 | 1914-1923 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T103 | 1928-1947 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T104 | 1928-1937 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T105 | 1938-1947 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T106 | 1953-1963 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
T107 | 1996-2001 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T108 | 2126-2145 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T109 | 2126-2135 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T110 | 2136-2145 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T111 | 2150-2169 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T112 | 2150-2159 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T113 | 2160-2169 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T114 | 2175-2184 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
T115 | 2190-2200 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T116 | 2201-2205 | Chemical | denotes | beta | http://purl.obolibrary.org/obo/CHEBI_10545 |
T117 | 2241-2246 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T118 | 2407-2426 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T119 | 2407-2416 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T120 | 2417-2426 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T121 | 2431-2442 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T122 | 2447-2457 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
T123 | 2510-2515 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T124 | 2791-2793 | Chemical | denotes | Hg | http://purl.obolibrary.org/obo/CHEBI_16170|http://purl.obolibrary.org/obo/CHEBI_25195 |
T126 | 2861-2880 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T127 | 2861-2870 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T128 | 2871-2880 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T129 | 3114-3133 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T130 | 3114-3123 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T131 | 3124-3133 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T132 | 3137-3147 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
T133 | 3151-3162 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T134 | 3205-3210 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T135 | 3449-3468 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T136 | 3449-3458 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T137 | 3459-3468 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T138 | 3473-3492 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T139 | 3473-3482 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T140 | 3483-3492 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T141 | 3579-3587 | Chemical | denotes | medicine | http://purl.obolibrary.org/obo/CHEBI_23888 |
T142 | 3621-3626 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T143 | 3744-3763 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T144 | 3744-3753 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T145 | 3754-3763 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T146 | 3777-3787 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T147 | 3797-3816 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T148 | 3797-3806 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T149 | 3807-3816 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T150 | 3830-3840 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T151 | 3903-3908 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T152 | 4026-4045 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T153 | 4026-4035 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T154 | 4036-4045 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T155 | 4059-4069 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T156 | 4079-4098 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T157 | 4079-4088 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T158 | 4089-4098 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T159 | 4112-4122 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T160 | 4195-4200 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T161 | 4326-4345 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T162 | 4326-4335 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T163 | 4336-4345 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T164 | 4351-4369 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T165 | 4374-4393 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T166 | 4374-4383 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T167 | 4384-4393 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T168 | 4399-4417 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T169 | 4423-4433 | Chemical | denotes | levamisole | http://purl.obolibrary.org/obo/CHEBI_6432 |
T170 | 4444-4454 | Chemical | denotes | budesonide | http://purl.obolibrary.org/obo/CHEBI_3207 |
T171 | 4460-4470 | Chemical | denotes | formoterol | http://purl.obolibrary.org/obo/CHEBI_5147 |
T172 | 4678-4697 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T173 | 4678-4687 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T174 | 4688-4697 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T175 | 4702-4720 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T176 | 4725-4733 | Chemical | denotes | losartan | http://purl.obolibrary.org/obo/CHEBI_6541 |
T177 | 4929-4948 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T178 | 4929-4938 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T179 | 4939-4948 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T180 | 4953-4971 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T181 | 4976-4995 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T182 | 4976-4985 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T183 | 4986-4995 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T184 | 5001-5011 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T185 | 5012-5016 | Chemical | denotes | beta | http://purl.obolibrary.org/obo/CHEBI_10545 |
T186 | 5024-5034 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T187 | 5225-5244 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T188 | 5225-5234 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T189 | 5235-5244 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T190 | 5248-5258 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
T191 | 5262-5273 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T192 | 5277-5295 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T193 | 5299-5310 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T194 | 5328-5340 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T195 | 5365-5384 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T196 | 5365-5374 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T197 | 5375-5384 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T198 | 5388-5398 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
T199 | 5402-5413 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T200 | 5417-5435 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T201 | 5439-5450 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T202 | 5468-5480 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T203 | 5771-5781 | Chemical | denotes | colchicine | http://purl.obolibrary.org/obo/CHEBI_23359 |
T204 | 5799-5818 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T205 | 5799-5808 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T206 | 5809-5818 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T207 | 5898-5903 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T208 | 6018-6029 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T209 | 6035-6046 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T210 | 6051-6062 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T211 | 6068-6087 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T212 | 6068-6077 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T213 | 6078-6087 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T214 | 6126-6145 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T215 | 6126-6135 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T216 | 6136-6145 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T217 | 6151-6162 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T218 | 6167-6176 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T219 | 6177-6186 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T220 | 6192-6203 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T221 | 6208-6219 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T222 | 6225-6244 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T223 | 6225-6234 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T224 | 6235-6244 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T225 | 6249-6258 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T226 | 6259-6268 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T227 | 6274-6285 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T228 | 6291-6302 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T229 | 6307-6316 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T230 | 6317-6326 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T231 | 6332-6343 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T232 | 6349-6360 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T233 | 6412-6417 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T234 | 6536-6545 | Chemical | denotes | Adenosine | http://purl.obolibrary.org/obo/CHEBI_16335 |
T235 | 6665-6675 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T236 | 6872-6882 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T237 | 7073-7083 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T238 | 7150-7155 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T239 | 7242-7248 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T240 | 7311-7321 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T241 | 7390-7395 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T242 | 7490-7500 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T243 | 7672-7682 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T244 | 7687-7705 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T245 | 7710-7720 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T246 | 7726-7744 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T247 | 7777-7782 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T248 | 7918-7937 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T249 | 7918-7927 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T250 | 7928-7937 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T251 | 7942-7960 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T252 | 7965-7984 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T253 | 7965-7974 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T254 | 7975-7984 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T255 | 7990-8000 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T256 | 8001-8005 | Chemical | denotes | beta | http://purl.obolibrary.org/obo/CHEBI_10545 |
T257 | 8013-8023 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T258 | 8198-8207 | Chemical | denotes | Darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T259 | 8208-8218 | Chemical | denotes | cobicistat | http://purl.obolibrary.org/obo/CHEBI_72291 |
T260 | 8219-8228 | Chemical | denotes | Darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T261 | 8246-8264 | Chemical | denotes | protease inhibitor | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
T263 | 8255-8264 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T264 | 8282-8298 | Chemical | denotes | CYP3A4 inhibitor | http://purl.obolibrary.org/obo/CHEBI_86501 |
T265 | 8289-8298 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T266 | 8311-8320 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T267 | 8368-8377 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T268 | 8378-8388 | Chemical | denotes | cobicistat | http://purl.obolibrary.org/obo/CHEBI_72291 |
T269 | 8452-8457 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T270 | 8645-8669 | Chemical | denotes | RNA polymerase inhibitor | http://purl.obolibrary.org/obo/CHEBI_37416 |
T271 | 8660-8669 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T272 | 8768-8779 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T273 | 8816-8826 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
T274 | 8898-8909 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T275 | 8999-9010 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T276 | 9015-9026 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T277 | 9031-9042 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T278 | 9048-9059 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T279 | 9092-9097 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T280 | 9199-9210 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T281 | 9216-9227 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T282 | 9232-9243 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T283 | 9249-9268 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T284 | 9249-9258 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T285 | 9259-9268 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T286 | 9307-9326 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T287 | 9307-9316 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T288 | 9317-9326 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T289 | 9332-9343 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T290 | 9348-9357 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T291 | 9358-9367 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T292 | 9373-9384 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T293 | 9389-9400 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T294 | 9406-9425 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T295 | 9406-9415 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T296 | 9416-9425 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T297 | 9430-9439 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T298 | 9440-9449 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T299 | 9455-9466 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T300 | 9472-9483 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T301 | 9488-9497 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T302 | 9498-9507 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T303 | 9513-9524 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T304 | 9530-9541 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T305 | 9593-9598 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T306 | 9722-9740 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T307 | 9746-9755 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T308 | 9756-9766 | Chemical | denotes | cobicistat | http://purl.obolibrary.org/obo/CHEBI_72291 |
T309 | 9820-9825 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T310 | 9991-10002 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T311 | 10008-10019 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T312 | 10024-10035 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T313 | 10307-10318 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T314 | 10372-10377 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T315 | 10441-10453 | Chemical | denotes | nucleic acid | http://purl.obolibrary.org/obo/CHEBI_33696 |
T316 | 10449-10453 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
T317 | 10546-10557 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T318 | 10563-10574 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T319 | 10579-10590 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T320 | 10596-10615 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T321 | 10596-10605 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T322 | 10606-10615 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T323 | 10654-10673 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T324 | 10654-10663 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T325 | 10664-10673 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T326 | 10679-10690 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T327 | 10695-10704 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T328 | 10705-10714 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T329 | 10720-10731 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T330 | 10736-10747 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T331 | 10753-10772 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T332 | 10753-10762 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T333 | 10763-10772 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T334 | 10777-10786 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T335 | 10787-10796 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T336 | 10802-10813 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T337 | 10819-10830 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T338 | 10835-10844 | Chemical | denotes | darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T339 | 10845-10854 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T340 | 10860-10871 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T341 | 10877-10888 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T342 | 10940-10945 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T343 | 11095-11104 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T344 | 11203-11214 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T345 | 11251-11261 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
T346 | 11333-11344 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T347 | 11434-11444 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
T348 | 11508-11513 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T349 | 11622-11633 | Chemical | denotes | Chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T350 | 11635-11653 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T351 | 11724-11726 | Chemical | denotes | Ph | http://purl.obolibrary.org/obo/CHEBI_30396 |
T352 | 11892-11910 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T353 | 12067-12072 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T354 | 12341-12359 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T355 | 12364-12377 | Chemical | denotes | ascorbic acid | http://purl.obolibrary.org/obo/CHEBI_22652|http://purl.obolibrary.org/obo/CHEBI_29073 |
T357 | 12373-12377 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
T358 | 12549-12560 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T359 | 12566-12584 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T360 | 12590-12602 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T361 | 12607-12618 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T362 | 12624-12642 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T363 | 12675-12680 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T364 | 12886-12904 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T365 | 12953-12958 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T366 | 13088-13106 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T367 | 13187-13197 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T368 | 13478-13496 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T369 | 13724-13743 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T370 | 13724-13733 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T371 | 13734-13743 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T372 | 13974-13992 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T373 | 14288-14298 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T374 | 14303-14321 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T375 | 14326-14336 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T376 | 14342-14360 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T377 | 14393-14398 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T378 | 14534-14553 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T379 | 14534-14543 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T380 | 14544-14553 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T381 | 14558-14576 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T382 | 14581-14589 | Chemical | denotes | losartan | http://purl.obolibrary.org/obo/CHEBI_6541 |
T383 | 14810-14828 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T384 | 14834-14846 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T385 | 14851-14869 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T386 | 14875-14887 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T387 | 14933-14938 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T388 | 15174-15193 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T389 | 15174-15183 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T390 | 15184-15193 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T391 | 15198-15216 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T392 | 15221-15240 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T393 | 15221-15230 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T394 | 15231-15240 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T395 | 15246-15256 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T396 | 15257-15261 | Chemical | denotes | beta | http://purl.obolibrary.org/obo/CHEBI_10545 |
T397 | 15269-15279 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T398 | 15637-15652 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T399 | 15743-15761 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
T400 | 15822-15827 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T401 | 15942-15960 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
T402 | 16014-16019 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T403 | 16132-16137 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
T404 | 16138-16148 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T405 | 16154-16172 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
T406 | 16178-16188 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
T407 | 16193-16204 | Chemical | denotes | thalidomide | http://purl.obolibrary.org/obo/CHEBI_9513 |
T408 | 16218-16223 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
T409 | 16224-16234 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T410 | 16240-16258 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
T411 | 16264-16274 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
T412 | 16466-16484 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
T413 | 16517-16522 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T414 | 16669-16671 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T416 | 16699-16717 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
T417 | 16750-16755 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T418 | 16895-16906 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T419 | 16948-16950 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T421 | 16964-16966 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T423 | 17155-17166 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T424 | 17220-17225 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T425 | 17384-17395 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T426 | 17400-17411 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T427 | 17416-17427 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
T428 | 17433-17444 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T429 | 17477-17482 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T430 | 17584-17595 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T431 | 17788-17799 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T432 | 17805-17823 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T433 | 17829-17841 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T434 | 17846-17857 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T435 | 17863-17881 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T436 | 17914-17919 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T437 | 18109-18120 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T438 | 18141-18152 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T439 | 18254-18259 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T440 | 18350-18361 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T441 | 18380-18391 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T442 | 18541-18546 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T443 | 18644-18650 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T444 | 18696-18707 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T445 | 18734-18736 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T447 | 18748-18758 | Chemical | denotes | antagonist | http://purl.obolibrary.org/obo/CHEBI_48706 |
T448 | 18822-18833 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T449 | 18887-18892 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T450 | 19031-19050 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T451 | 19031-19040 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T452 | 19041-19050 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T453 | 19054-19064 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
T454 | 19068-19079 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T455 | 19122-19127 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T456 | 19373-19375 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T458 | 19388-19390 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T460 | 19563-19573 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T461 | 19650-19655 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T462 | 19758-19769 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T463 | 19796-19798 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T465 | 19810-19820 | Chemical | denotes | antagonist | http://purl.obolibrary.org/obo/CHEBI_48706 |
T466 | 19884-19895 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T467 | 19949-19954 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T468 | 20066-20071 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T469 | 20072-20077 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T470 | 20245-20250 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T471 | 20326-20336 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T472 | 20337-20348 | Chemical | denotes | ruxolitinib | http://purl.obolibrary.org/obo/CHEBI_66919 |
T473 | 20366-20377 | Chemical | denotes | tofacitinib | http://purl.obolibrary.org/obo/CHEBI_71200 |
T474 | 20571-20573 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T476 | 20695-20701 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T477 | 20742-20748 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T3 | 3329-3341 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
T4 | 5706-5718 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
T5 | 8583-8593 | http://purl.obolibrary.org/obo/GO_0046903 | denotes | secretions |
T6 | 11079-11094 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
T7 | 11756-11767 | http://purl.obolibrary.org/obo/GO_0140253 | denotes | cell fusion |
T8 | 11756-11767 | http://purl.obolibrary.org/obo/GO_0045026 | denotes | cell fusion |
T9 | 11756-11767 | http://purl.obolibrary.org/obo/GO_0000768 | denotes | cell fusion |
T10 | 11756-11767 | http://purl.obolibrary.org/obo/GO_0000747 | denotes | cell fusion |
T11 | 11791-11804 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
T12 | 19246-19258 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T88 | 0-175 | Sentence | denotes | Table 2 Available and ongoing RCT on anti-infective and anti-inflammatory drugs most provided as off-label/compassionate treatments in the first phase of the COVID-19 pandemic |
T89 | 176-327 | Sentence | denotes | Drug Class/mechanism Published RCT Ongoing RCT for treatment/prevention of COVID-19 (recruiting or not yet recruiting) registered at ClinicalTrials.gov |
T90 | 328-394 | Sentence | denotes | Lopinavir/ritonavir Lopinavir is an HIV type 1 protease inhibitor. |
T91 | 395-587 | Sentence | denotes | Ritonavir is a CYP3A4 inhibitor that boosts lopinavir concentrations • Open-label RCT comparing lopinavir/ritonavir (99 patients) vs. standard of care (100) in patients with COVID-19 in China. |
T92 | 588-665 | Sentence | denotes | Lopinavir/ritonavir was administered at the dosage of 400/100 mg for 14 days. |
T93 | 666-745 | Sentence | denotes | The primary time-to-event endpoint was clinical improvement from randomization. |
T94 | 746-1134 | Sentence | denotes | In the primary study population (ITT), no statistically significant differences were observed with regard to the primary endpoint of clinical improvement (HR 1.24 with standard of care as reference, 95% CI 0.90 to 1.72) and the secondary endpoint of 28-day mortality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). |
T95 | 1135-1288 | Sentence | denotes | In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. |
T96 | 1289-1461 | Sentence | denotes | Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. |
T97 | 1462-1503 | Sentence | denotes | Open-label RCT (NCT04307693, recruiting). |
T98 | 1504-1563 | Sentence | denotes | Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18. |
T99 | 1564-1667 | Sentence | denotes | • Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. |
T100 | 1668-1717 | Sentence | denotes | Open-label RCT (NCT04261907, not yet recruiting). |
T101 | 1718-1887 | Sentence | denotes | Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute). |
T102 | 1888-1990 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19. |
T103 | 1991-2032 | Sentence | denotes | Open-label RCT (NCT04252885, recruiting). |
T104 | 2033-2109 | Sentence | denotes | Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21. |
T105 | 2110-2235 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19. |
T106 | 2236-2277 | Sentence | denotes | Open-label RCT (NCT04276688, recruiting). |
T107 | 2278-2360 | Sentence | denotes | Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days). |
T108 | 2361-2504 | Sentence | denotes | • Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. |
T109 | 2505-2546 | Sentence | denotes | Open-label RCT (NCT04255017, recruiting). |
T110 | 2547-2822 | Sentence | denotes | Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 > 93% or Pao 2/Fio 2 > 300 mm Hg); (b) time to lung recovery. |
T111 | 2823-2935 | Sentence | denotes | • Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. |
T112 | 2936-2987 | Sentence | denotes | Double-blind RCT (NCT04328285, not yet recruiting). |
T113 | 2988-3082 | Sentence | denotes | Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months). |
T114 | 3083-3199 | Sentence | denotes | • Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. |
T115 | 3200-3249 | Sentence | denotes | Open-label RCT (NCT04286503, not yet recruiting). |
T116 | 3250-3432 | Sentence | denotes | Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT. |
T117 | 3433-3615 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19. |
T118 | 3616-3665 | Sentence | denotes | Open-label RCT (NCT04295551, not yet recruiting). |
T119 | 3666-3727 | Sentence | denotes | Primary endpoint: clinical recovery time (follow-up 28 days). |
T120 | 3728-3897 | Sentence | denotes | • Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19. |
T121 | 3898-3947 | Sentence | denotes | Open-label RCT (NCT04275388, not yet recruiting). |
T122 | 3948-4009 | Sentence | denotes | Primary endpoint: clinical recovery time (follow-up 14 days). |
T123 | 4010-4189 | Sentence | denotes | • Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. |
T124 | 4190-4231 | Sentence | denotes | Open-label RCT (NCT04251871, recruiting). |
T125 | 4232-4309 | Sentence | denotes | Primary endpoint: time to complete remission of symptoms (follow-up 28 days). |
T126 | 4310-4525 | Sentence | denotes | • Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia. |
T127 | 4526-4579 | Sentence | denotes | Partly blinded RCT (NCT04331470, not yet recruiting). |
T128 | 4580-4661 | Sentence | denotes | Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days. |
T129 | 4662-4773 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. |
T130 | 4774-4835 | Sentence | denotes | Double-blind, adaptive RCT (NCT04328012, not yet recruiting). |
T131 | 4836-4912 | Sentence | denotes | Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days). |
T132 | 4913-5082 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. |
T133 | 5083-5136 | Sentence | denotes | Double-blind, adaptive RCT (NCT04315948, recruiting). |
T134 | 5137-5208 | Sentence | denotes | Primary endpoint: severity rating on a 7-point ordinal scale at day 15. |
T135 | 5209-5508 | Sentence | denotes | • Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19. |
T136 | 5509-5560 | Sentence | denotes | Single-blind RCT (NCT04323345, not yet recruiting). |
T137 | 5561-5754 | Sentence | denotes | Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days). |
T138 | 5755-5892 | Sentence | denotes | • Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. |
T139 | 5893-5942 | Sentence | denotes | Open-label RCT (NCT04328480, not yet recruiting). |
T140 | 5943-6001 | Sentence | denotes | Primary endpoint: all-cause mortality (follow-up 30 days). |
T141 | 6002-6406 | Sentence | denotes | • Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. |
T142 | 6407-6456 | Sentence | denotes | Open-label RCT (NCT04303299, not yet recruiting). |
T143 | 6457-6524 | Sentence | denotes | Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks). |
T144 | 6525-6555 | Sentence | denotes | Remdesivir Adenosine analogue. |
T145 | 6556-6721 | Sentence | denotes | It binds to RNA-dependent RNA polymerase and acts as an RNA-chain terminator • Not available • Comparison of remdesivir vs. placebo in patients with severe COVID-19. |
T146 | 6722-6765 | Sentence | denotes | Double-blind RCT (NCT04257656, recruiting). |
T147 | 6766-6855 | Sentence | denotes | Primary endpoint: clinical status, assessed by an ordinal scale at days 7, 14, 21 and 28. |
T148 | 6856-6938 | Sentence | denotes | • Comparison of remdesivir vs. placebo in patients with mild to moderate COVID-19. |
T149 | 6939-6982 | Sentence | denotes | Double-blind RCT (NCT04252664, recruiting). |
T150 | 6983-7056 | Sentence | denotes | Primary endpoint: time to clinical recovery in hours (follow-up 28 days). |
T151 | 7057-7144 | Sentence | denotes | • Comparison of remdesivir vs. local standard of care in patients with severe COVID-19. |
T152 | 7145-7186 | Sentence | denotes | Open-label RCT (NCT04252664, recruiting). |
T153 | 7187-7294 | Sentence | denotes | Primary endpoint: composite of fever normalization and oxygen saturation normalization (follow-up 14 days). |
T154 | 7295-7384 | Sentence | denotes | • Comparison of remdesivir vs. local standard of care in patients with moderate COVID-19. |
T155 | 7385-7426 | Sentence | denotes | Open-label RCT (NCT04292730, recruiting). |
T156 | 7427-7473 | Sentence | denotes | Primary endpoint: discharged status at day 14. |
T157 | 7474-7539 | Sentence | denotes | • Comparison of remdesivir vs. placebo in patients with COVID-19. |
T158 | 7540-7583 | Sentence | denotes | Double-blind RCT (NCT04280705, recruiting). |
T159 | 7584-7655 | Sentence | denotes | Primary endpoint: severity rating on a 8-point ordinal scale at day 15. |
T160 | 7656-7771 | Sentence | denotes | • Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19. |
T161 | 7772-7830 | Sentence | denotes | Open-label adaptive RCT (NCT04321616, not yet recruiting). |
T162 | 7831-7901 | Sentence | denotes | Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks). |
T163 | 7902-8071 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. |
T164 | 8072-8125 | Sentence | denotes | Double-blind, adaptive RCT (NCT04315948, recruiting). |
T165 | 8126-8197 | Sentence | denotes | Primary endpoint: severity rating on a 7-point ordinal scale at day 15. |
T166 | 8198-8265 | Sentence | denotes | Darunavir/cobicistat Darunavir is an HIV type 1 protease inhibitor. |
T167 | 8266-8446 | Sentence | denotes | Cobicistat is a CYP3A4 inhibitor that boosts darunavir concentrations • Not available • Comparison of darunavir/cobicistat vs. standard of care in patients with COVID-19 pneumonia. |
T168 | 8447-8488 | Sentence | denotes | Open-label RCT (NCT04252274, recruiting). |
T169 | 8489-8603 | Sentence | denotes | Primary endpoint: virologic clearance rate of throat swabs, sputum or lower respiratory tract secretions at day 7. |
T170 | 8604-8910 | Sentence | denotes | Favipiravir Anti-influenza RNA-dependent RNA polymerase inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir. |
T171 | 8911-9086 | Sentence | denotes | The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. |
T172 | 9087-9128 | Sentence | denotes | Open-label RCT (NCT04310228, recruiting). |
T173 | 9129-9182 | Sentence | denotes | Primary endpoint: clinical cure (follow-up 3 months). |
T174 | 9183-9587 | Sentence | denotes | • Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. |
T175 | 9588-9637 | Sentence | denotes | Open-label RCT (NCT04303299, not yet recruiting). |
T176 | 9638-9705 | Sentence | denotes | Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks). |
T177 | 9706-9814 | Sentence | denotes | • Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. |
T178 | 9815-9856 | Sentence | denotes | Open-label RCT (NCT04304053, recruiting). |
T179 | 9857-9974 | Sentence | denotes | Primary endpoint: incidence of secondary cases among contacts of a case and contacts of contacts (follow-up 14 days). |
T180 | 9975-10074 | Sentence | denotes | • Comparison of chloroquine plus favipiravir vs. favipiravir vs. placebo in patients with COVID-19. |
T181 | 10075-10118 | Sentence | denotes | Double-blind RCT (NCT04319900, recruiting). |
T182 | 10119-10290 | Sentence | denotes | Primary endpoints: (a) time to improvement/recovery and frequency of improvement/recovery (follow-up 10 days); (b) time to negative swab/sputum RT-PCR (follow-up 10 days). |
T183 | 10291-10366 | Sentence | denotes | • Comparison of favipiravir vs. standard of care in patients with COVID-19. |
T184 | 10367-10416 | Sentence | denotes | Open-label RCT (NCT04333589, not yet recruiting). |
T185 | 10417-10529 | Sentence | denotes | Primary endpoint: viral nucleic acid test negative conversion rate in nasopharyngeal swabs (follow-up 5 months). |
T186 | 10530-10934 | Sentence | denotes | • Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. |
T187 | 10935-10984 | Sentence | denotes | Open-label RCT (NCT04303299, not yet recruiting). |
T188 | 10985-11052 | Sentence | denotes | Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks). |
T189 | 11053-11345 | Sentence | denotes | Umifenovir Anti-influenza membrane fusion inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir. |
T190 | 11346-11502 | Sentence | denotes | The manuscript is publicly available but still to be peer reviewed [30] • Comparison of umifenovir vs. standard of care in patients with COVID-19 pneumonia. |
T191 | 11503-11552 | Sentence | denotes | Open-label RCT (NCT04260594, not yet recruiting). |
T192 | 11553-11621 | Sentence | denotes | Primary endpoint: virus negative conversion rate (follow-up 7 days). |
T193 | 11622-12001 | Sentence | denotes | Chloroquine, hydroxychloroquine Some proposed mechanisms are the following: increase in the endosomal Ph necessary for the virus/host cell fusion; interference with the glycosylation of cell receptors; immunomodulatory activity • Not available • Comparison of different hydroxychloroquine dosages vs. placebo in three cohorts (outpatients, inpatients, healthcare workers a risk). |
T194 | 12002-12126 | Sentence | denotes | Double-blind RCT for outpatients and healthcare workers and open-label RCT for inpatients (NCT04329923, not yet recruiting). |
T195 | 12127-12324 | Sentence | denotes | Primary endpoints: (a) release from quarantine (outpatients, follow-up 14 days); (b) discharge (inpatients, follow-up 14 days); (c) development of COVID-19 (healthcare workers, follow-up 2 months). |
T196 | 12325-12411 | Sentence | denotes | • Comparison of hydroxychloroquine vs. ascorbic acid in contacts of COVID-19 patients. |
T197 | 12412-12463 | Sentence | denotes | Double-blind RCT (NCT04328961, not yet recruiting). |
T198 | 12464-12532 | Sentence | denotes | Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days). |
T199 | 12533-12669 | Sentence | denotes | • Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. |
T200 | 12670-12719 | Sentence | denotes | Open-label RCT (NCT04332094, not yet recruiting). |
T201 | 12720-12947 | Sentence | denotes | Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs. ciclesonide in patients with COVID-19. |
T202 | 12948-12997 | Sentence | denotes | Open-label RCT (NCT04330586, not yet recruiting). |
T203 | 12998-13071 | Sentence | denotes | Primary endpoint: SARS-CoV-2 eradication (based on virus load) at day 14. |
T204 | 13072-13198 | Sentence | denotes | • Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. |
T205 | 13199-13250 | Sentence | denotes | Double-blind RCT (NCT04330495, not yet recruiting). |
T206 | 13251-13461 | Sentence | denotes | Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks). |
T207 | 13462-13570 | Sentence | denotes | • Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. |
T208 | 13571-13622 | Sentence | denotes | Double-blind RCT (NCT04328467, not yet recruiting). |
T209 | 13623-13685 | Sentence | denotes | Primary endpoint: prevalence of COVID-19 (follow-up 12 weeks). |
T210 | 13686-13798 | Sentence | denotes | • Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. |
T211 | 13799-13850 | Sentence | denotes | Double-blind RCT (NCT04328285, not yet recruiting). |
T212 | 13851-13868 | Sentence | denotes | Primary endpoint: |
T213 | 13869-13957 | Sentence | denotes | Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months). |
T214 | 13958-14079 | Sentence | denotes | • Comparison of hydroxychloroquine vs. placebo in symptomatic COVID-19 patients or exposed healthcare workers/households. |
T215 | 14080-14123 | Sentence | denotes | Double-blind RCT (NCT04308668, recruiting). |
T216 | 14124-14271 | Sentence | denotes | Primary endpoints: (a) incidence of symptomatic COVID-19 among asymptomatic participants; (b) severity rating on a 3-point ordinal scale at day 14. |
T217 | 14272-14387 | Sentence | denotes | • Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19. |
T218 | 14388-14446 | Sentence | denotes | Open-label adaptive RCT (NCT04321616, not yet recruiting). |
T219 | 14447-14517 | Sentence | denotes | Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks). |
T220 | 14518-14629 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. |
T221 | 14630-14691 | Sentence | denotes | Double-blind, adaptive RCT (NCT04328012, not yet recruiting). |
T222 | 14692-14768 | Sentence | denotes | Primary endpoint: NIAID COVID-19 Ordinal Severity Scale (follow-up 60 days). |
T223 | 14769-14927 | Sentence | denotes | • Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19. |
T224 | 14928-14977 | Sentence | denotes | Open-label RCT (NCT04332835, not yet recruiting). |
T225 | 14978-15157 | Sentence | denotes | Primary endpoints: (a) change in virus load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at days 0, 4, 7, 14 and 28. |
T226 | 15158-15327 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. |
T227 | 15328-15381 | Sentence | denotes | Double-blind, adaptive RCT (NCT04315948, recruiting). |
T228 | 15382-15453 | Sentence | denotes | Primary endpoint: severity rating on a 7-point ordinal scale at day 15. |
T229 | 15454-15816 | Sentence | denotes | Methylprednisolone A subgroup of patients with severe COVID-19 might develop a cytokine storm syndrome which causes rapidly progressive pneumonia, ARDS and clinical deterioration and corticosteroids administration may halt the dysregulated cytokine release • Not available • Comparison of methylprednisolone vs. standard of care in patients with severe COVID-19. |
T230 | 15817-15858 | Sentence | denotes | Open-label RCT (NCT04244591, recruiting). |
T231 | 15859-15925 | Sentence | denotes | Primary endpoint: lower Murray lung injury score at days 7 and 14. |
T232 | 15926-16008 | Sentence | denotes | • Comparison of methylprednisolone vs. standard of care in patients with COVID-19. |
T233 | 16009-16050 | Sentence | denotes | Open-label RCT (NCT04273321, recruiting). |
T234 | 16051-16107 | Sentence | denotes | Primary endpoint: treatment failure (follow-up 14 days). |
T235 | 16108-16308 | Sentence | denotes | • Comparison of inhaled alpha interferon plus methylprednisolone plus umifenovir vs. thalidomide plus inhaled alpha interferon plus methylprednisolone plus umifenovir in patients with severe COVID-19. |
T236 | 16309-16360 | Sentence | denotes | Double-blind RCT (NCT04273581, not yet recruiting). |
T237 | 16361-16428 | Sentence | denotes | Primary endpoint: time to clinical improvement (follow-up 28 days). |
T238 | 16429-16511 | Sentence | denotes | • Comparison of different dosages of methylprednisolone in patients with COVID-19. |
T239 | 16512-16553 | Sentence | denotes | Open-label RCT (NCT04263402, recruiting). |
T240 | 16554-16635 | Sentence | denotes | Primary endpoints: (a) disease readmission at day 7; (b) critical stage at day 7. |
T241 | 16636-16744 | Sentence | denotes | • Comparison of siltuximab (anti–IL-6 monoclonal antibody) vs. methylprednisolone in patients with COVID-19. |
T242 | 16745-16794 | Sentence | denotes | Open-label RCT (NCT04329650, not yet recruiting). |
T243 | 16795-16846 | Sentence | denotes | Primary endpoint: ICU admission (follow-up 29 days) |
T244 | 16847-16963 | Sentence | denotes | Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. |
T245 | 16964-17214 | Sentence | denotes | IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. |
T246 | 17215-17264 | Sentence | denotes | Open-label RCT (NCT04331808, not yet recruiting). |
T247 | 17265-17367 | Sentence | denotes | Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale). |
T248 | 17368-17471 | Sentence | denotes | • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. |
T249 | 17472-17513 | Sentence | denotes | Open-label RCT (NCT04310228, recruiting). |
T250 | 17514-17567 | Sentence | denotes | Primary endpoint: clinical cure (follow-up 3 months). |
T251 | 17568-17647 | Sentence | denotes | • Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. |
T252 | 17648-17699 | Sentence | denotes | Double-blind RCT (NCT04320615, not yet recruiting). |
T253 | 17700-17771 | Sentence | denotes | Primary endpoint: severity rating on a 7-point ordinal scale at day 28. |
T254 | 17772-17908 | Sentence | denotes | • Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. |
T255 | 17909-17958 | Sentence | denotes | Open-label RCT (NCT04332094, not yet recruiting). |
T256 | 17959-18092 | Sentence | denotes | Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks). |
T257 | 18093-18248 | Sentence | denotes | • Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. |
T258 | 18249-18298 | Sentence | denotes | Open-label RCT (NCT04333914, not yet recruiting). |
T259 | 18299-18316 | Sentence | denotes | Primary endpoint: |
T260 | 18317-18333 | Sentence | denotes | 28-day survival. |
T261 | 18334-18535 | Sentence | denotes | • Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. |
T262 | 18536-18585 | Sentence | denotes | Open-label RCT (NCT04322773, not yet recruiting). |
T263 | 18586-18679 | Sentence | denotes | Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days). |
T264 | 18680-18881 | Sentence | denotes | • Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. |
T265 | 18882-18931 | Sentence | denotes | Open-label RCT (NCT04330638, not yet recruiting). |
T266 | 18932-18999 | Sentence | denotes | Primary endpoint: time to clinical improvement (follow-up 15 days). |
T267 | 19000-19116 | Sentence | denotes | • Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. |
T268 | 19117-19166 | Sentence | denotes | Open-label RCT (NCT04286503, not yet recruiting). |
T269 | 19167-19349 | Sentence | denotes | Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT. |
T270 | 19350-19387 | Sentence | denotes | Anakinra Antagonist of IL-1 receptor. |
T271 | 19388-19644 | Sentence | denotes | IL-1 is one of the main drivers of immunologic response and symptoms in patients with cytokine-release syndrome. • Not available • Comparison of anakinra vs. emapalumab (anti–interferon γ monoclonal antibody) vs. standard of care in patients with COVID-19. |
T272 | 19645-19694 | Sentence | denotes | Open-label RCT (NCT04324021, not yet recruiting). |
T273 | 19695-19741 | Sentence | denotes | Primary endpoint: treatment success at day 15. |
T274 | 19742-19943 | Sentence | denotes | • Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. |
T275 | 19944-19993 | Sentence | denotes | Open-label RCT (NCT04330638, not yet recruiting). |
T276 | 19994-20061 | Sentence | denotes | Primary endpoint: time to clinical improvement (follow-up 15 days). |
T277 | 20062-20195 | Sentence | denotes | Off-label drugs mostly provided in Italy during the first phase of the COVID-19 pandemic according to the authors' direct experience. |
T278 | 20196-20379 | Sentence | denotes | Of note, there are also registered RCT for other drugs to be investigated in patients with COVID-19 (e.g. the Janus kinase family inhibitors ruxolitinib, baricitinib and tofacitinib). |
T279 | 20380-20899 | Sentence | denotes | ARDS = acute respiratory distress syndrome; CI, confidence interval; COVID-19, coronavirus disease 2019; CT, computed tomography; EOT, end of treatment; HR, hazard ratio; Ig, immunoglobulin; IL-1, interleukin 1; IQR, interquartile range; ITT, intent to treat; mITT, modified intent to treat; Pao2/Fio2, of arterial oxygen partial pressure to fractional inspired oxygen; RCT, randomized controlled trial; RT-PCR, real-time PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization. |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32360444-32187464-22369752 | 1367-1369 | 32187464 | denotes | 22 |